1-20 of 53
Christopher P. Venner, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy of Daratumumab Containing Regimens Post Lenalidomide Maintenance in Transplant Eligible Patients: Real-World Experience from the Canadian Myeloma Research Group Database

Hira S Mian, MD, Christine Eisfeld, Christopher P. Venner, MD, Victor Jimenez-Zepeda, MD, Cyrus Khandanpour, MD, Arleigh McCurdy, MD BSc, Michael Sebag, MD PhD FRCPC, Kevin W Song, MD FRCPC, Richard Leblanc, MD FRCPC, Esther Masih-Khan, PhD, Eshetu G Atenafu, MSc, P.Stat, Darrell J White, MD, Julie Stakiw, MD, Anthony Reiman, MD, Martha L Louzada, MDMSc, Muhammad Aslam, MD, Rami Kotb, MD, Engin Gul, BS, MBA, Donna E. Reece, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 26–27.
https://doi.org/10.1182/blood-2020-133372
Published: 2020
Journal Articles

Peripheral Neuropathy Symptoms, Pain and Functioning in Relapsed or Refractory Multiple Myeloma Patients Treated with Selinexor, Bortezomib, and Dexamethasone

Larysa Sanchez, MD, Xavier Leleu, MD, Jennifer Beaumont, Hailin Yu, Stacie Hudgens, MA, Holger W Auner, MD PhD, Hang Quach, MD, Sosana Delimpasi, MD, Ivan Spicka, MD PhD, Luděk Pour, MD, Meletios A Dimopoulos, Halyna Pylypenko, MD, Vadim A Doronin, MD, Ganna Usenko, MD, Roman Hajek, MD PhD, Reuben Benjamin, MD, Christopher P. Venner, MD, Mamta Garg, MD FRCP, FRCPath, Don A. Stevens, MD, Sundar Jagannath, MD, Philippe Moreau, MD, Moshe Levy, MD, Nizar J. Bahlis, MD, Thierry Facon, MD, Yi Chai, Xiwen Ma, Shijie Tang, Hoyee Leong, Jatin J. Shah, MD, Sharon Shacham, PhD MBA, Michael G Kauffman, MD PhD, Paul G. Richardson, MD, Sebastian Grosicki, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 39–41.
https://doi.org/10.1182/blood-2020-141319
Published: 2020
Journal Articles

Once Weekly Selinexor, Bortezomib, and Dexamethasone Versus Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Age and Frailty Subgroup Analyses from the Phase 3 Boston Study

Holger W Auner, MD PhD, Maria Gavriatopoulou, Sosana Delimpasi, MD, Maryana Simonova, MD, Ivan Spicka, MD PhD, Ludek Pour, MD, Meletios A Dimopoulos, Irina Kryachok, Professor, Halyna Pylypenko, MD, Xavier Leleu, MD, Vadim A Doronin, MD, Ganna Usenko, MD, Roman Hajek, MD, Reuben Benjamin, FRCPath, MRCP, MBBS, PhD, Tuphan Kanti Dolai, MBBS, MD DNB, DM, Dinesh Kumar Sinha, MD, Christopher P. Venner, MD, Mamta Garg, MD FRCP, FRCPath, Don A. Stevens, MD, Hang Quach, MDFRACP,FRCPA,MBBS, Sundar Jagannath, MD, Philippe Moreau, MD, Moshe Y. Levy, MD, Ashraf Z. Badros, MD, Larry D. Anderson, Jr., MD PhD, Nizar J. Bahlis, MD, Thierry Facon, MD, Maria Mateos, MD PhD, Michele Cavo, Anita A. Joshi, Yi Chai, Melina Arazy, MD, Jatin Shah, MD, Sharon Shacham, PhD MBA, Michael G Kauffman, MD PhD, Paul G. Richardson, MD, Sebastian Grosicki, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 17–18.
https://doi.org/10.1182/blood-2020-137303
Published: 2020
Journal Articles

Impact of Prior Therapies on the Safety and Efficacy of Once Weekly Selinexor, Bortezomib, and Dexamethasone Compared with Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Results from the Boston Study

Maria Mateos, MD PhD, Sundar Jagannath, MD, Sosana Delimpasi, MD, Maryana Simonova, MD, Ivan Spicka, MD PhD, Ludek Pour, MD, Irina Kryachok, MD, Maria Gavriatopoulou, Meletios A Dimopoulos, Halyna Pylypenko, MD, Holger W Auner, MD PhD, Xavier Leleu, MD, Vadim A Doronin, MD, Ganna Usenko, MD, Reuben Benjamin, MD, Tuphan Kanti Dolai, MBBS, MD DNB, DM, Dinesh Kumar Sinha, MD, Christopher P. Venner, MD, Mamta Garg, MD FRCP, FRCPath, Don A. Stevens, MD, Hang Quach, MDFRACP,FRCPA,MBBS, Philippe Moreau, MD, Moshe Y. Levy, MD, Ashraf Z. Badros, MD, Larry D. Anderson, Jr., MD PhD, Nizar J. Bahlis, MD, Thierry Facon, MD, Michele Cavo, Yi Chai, Melina Arazy, MD, Jatin Shah, MD, Sharon Shacham, PhD MBA, Michael G Kauffman, MD PhD, Paul G. Richardson, MD, Sebastian Grosicki, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 50–52.
https://doi.org/10.1182/blood-2020-137574
Published: 2020
Journal Articles

Updated Analysis of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): The Phase 3 Maia Study

Shaji K. Kumar, MD, Thierry Facon, MD, Saad Z. Usmani, MDMBBS,MBA, Torben Plesner, MD DSc, Robert Z. Orlowski, MDPhD, Cyrille Touzeau, Supratik Basu, Nizar J. Bahlis, MD, Hartmut Goldschmidt, MD, Michael E. O'Dwyer, MD, Christopher P. Venner, MD, Katja Weisel, MD, Cyrille Hulin, MD, Lionel Karlin, MD, Meir Preis, MD PhD, Annemiek Broyl, MD PhD, William Renwick, Markus Hansson, MD, Maria Krevvata, PhD, Jianping Wang, Rian Van Rampelbergh, Jon Ukropec, PhD, Clarissa M. Uhlar, Rachel Kobos, MD, Aurore Perrot
Journal: Blood
Blood (2020) 136 (Supplement 1): 24–26.
https://doi.org/10.1182/blood-2020-134847
Published: 2020
Journal Articles

Effect of Prior Treatment with Proteasome Inhibitors on the Efficacy and Safety of Once-Weekly Selinexor, Bortezomib, and Dexamethasone in Comparison with Twice-Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis from the Boston Study

Maria Mateos, MD PhD, Maria Gavriatopoulou, Thierry Facon, MD, Holger W Auner, MD PhD, Xavier Leleu, MD, Roman Hajek, MD, Meletios A Dimopoulos, Sosana Delimpasi, MD, Maryana Simonova, MD, Ivan Spicka, MD PhD, Ludek Pour, MD, Irina Kryachok, MD, Halyna Pylypenko, MD, Vadim A Doronin, MD, Ganna Usenko, MD, Reuben Benjamin, FRCPath, MRCP, MBBS, PhD, Tuphan Kanti Dolai, MBBS, MD DNB, DM, Dinesh Kumar Sinha, MD, Christopher P. Venner, MD, Mamta Garg, MD FRCP, FRCPath, Don A. Stevens, MD, Hang Quach, MD, Sundar Jagannath, MD, Philippe Moreau, MD, Moshe Levy, MD, Ashraf Z. Badros, MD, Larry D. Anderson, Jr., MD PhD, Nizar J. Bahlis, MD, Michele Cavo, Yi Chai, Melina Arazy, MD, Jatin Shah, MD, Sharon Shacham, PhD MBA, Michael G Kauffman, MD PhD, Paul G. Richardson, MD, Sebastian Grosicki, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 48–50.
https://doi.org/10.1182/blood-2020-138391
Published: 2020
Journal Articles

Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda

Raymond L. Comenzo, MD, Efstathios Kastritis, MD, Giovanni Palladini, MD PhD, Monique C. Minnema, Ashutosh D. Wechalekar, MBBS,FRCP,FRCPath,DM, Arnaud Jaccard, MD PhD, Vaishali Sanchorawala, MD, Hans C. Lee, MD, Simon D. Gibbs, FRACP, FRCPA, MBBS, Peter Mollee, FRACP,MBBS,MSc,FRCPA, Christopher P. Venner, MD, Jin Lu, Stefan Schönland, MD, Moshe Gatt, MD, Kenshi Suzuki, MD PhD, Kihyun Kim, MD PhD, M. Teresa Cibeira, MD PhD, Meral Beksac, MD, Edward Libby, MD, Jason Valent, MD, Vania T. M. Hungria, MD PhD, Sandy W. Wong, MD, Michael Rosenzweig, MD, Naresh Bumma, MD, Dominique Chauveau, MD PhD, Meletios A Dimopoulos, NamPhuong Tran, MD, Xiang Qin, MD PhD, Sandra Y. Vasey, MSc, Brenda Tromp, MSc, Brendan M. Weiss, MD, Jessica Vermeulen, MD PhD, Giampaolo Merlini, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 48–50.
https://doi.org/10.1182/blood-2020-137582
Published: 2020
Journal Articles

Selinexor in Combination with Pomalidomide and Dexamethasone (SPd) for Treatment of Patients with Relapsed Refractory Multiple Myeloma (RRMM)

Christine I Chen, MD, Nizar J. Bahlis, MD, Cristina Gasparetto, MD, Sascha A Tuchman, MD, Brea Lipe, MD, Muhamed Baljevic, MD, Rami Kotb, MD, Heather J Sutherland, MD PhD, William I Bensinger, MD, Michael Sebag, MD PhD FRCPC, Richard LeBlanc, MD FRCPC, Christopher P. Venner, MD, Gary J. Schiller, MD, Suzanne Lentzsch, MD PhD, Natalie S. Callander, MD, Adriana C Rossi, MD MSc, Heidi Sheehan, Dane Van Domelen, PhD, Kai Kazuharu, MD PhD, Hongwei Wang, MD PhD, Jatin Shah, MD, Sharon Shacham, PhD MBA, Michael G Kauffman, MD PhD, Darrell J White, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 18–19.
https://doi.org/10.1182/blood-2020-139858
Published: 2020
Journal Articles

A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma

Michael Sebag, MD PhD FRCPC, Nizar J. Bahlis, MD, Christopher P. Venner, MD, Arleigh McCurdy, MD BSc, C. Tom Kouroukis, MDMSc,FRCPC, Jesse Shustik, MD, Rami Kotb, MD, Darrell J White, MD, Julie Stakiw, MD, Nicole B. Laferriere, MD PhD, Anthony Reiman, MD, Fernando Camacho, PhD, Molei Fu, Engin Gul, BSc, Donna E. Reece, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 6.
https://doi.org/10.1182/blood-2020-141087
Published: 2020
Journal Articles

Selinexor, Lenalidomide and Dexamethasone (SRd) for Patients with Relapsed/Refractory and Newly Diagnosed Multiple Myeloma

Darrell J White, MD, Richard LeBlanc, MD FRCPC, Muhamed Baljevic, MD, Nizar J. Bahlis, MD, Suzanne Lentzsch, MD PhD, Christopher P. Venner, MD, Cristina Gasparetto, MD, Christine I Chen, MD, Brea Lipe, MD, Sascha A Tuchman, MD, Heather J Sutherland, MD PhD, Rami Kotb, MD, Michael Sebag, MD PhD FRCPC, Natalie S. Callander, MD, William I Bensinger, MD, Adriana C Rossi, MD MSc, Heidi Sheehan, Dane Van Domelen, PhD, Tianjun Zhou, MD PhD, Kai Kazuharu, MD PhD, Jatin Shah, MD, Sharon Shacham, PhD MBA, Michael G Kauffman, MD PhD, Gary J. Schiller, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–46.
https://doi.org/10.1182/blood-2020-140141
Published: 2020
Journal Articles

Selinexor in Combination with Carfilzomib and Dexamethasone, All Once Weekly (SKd), for Patients with Relapsed/Refractory Multiple Myeloma

Cristina Gasparetto, MD, Brea Lipe, MD, Sascha A Tuchman, MD, Natalie S. Callander, MD, Suzanne Lentzsch, MD PhD, Muhamed Baljevic, MD, Adriana C Rossi, MD MSc, Nizar J. Bahlis, MD, Darrell J White, MD, Christine I Chen, MD, Heather J Sutherland, MD PhD, Rami Kotb, MD, Richard LeBlanc, MD FRCPC, Michael Sebag, MD PhD FRCPC, Christopher P. Venner, MD, William I Bensinger, MD, Heidi Sheehan, Dane Van Domelen, PhD, Kai Kazuharu, MD PhD, Gary J. Schiller, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 14–15.
https://doi.org/10.1182/blood-2020-137183
Published: 2020
Journal Articles

Once Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma: High-Risk Cytogenetic Risk Planned Subgroup Analyses from the Phase 3 Boston Study

Shambavi Richard, MD, Ajai Chari, MD, Sosana Delimpasi, MD, Maryana Simonova, MD, Ivan Spicka, MD PhD, Ludek Pour, MD, Irina Kryachok, MD, Meletios A Dimopoulos, Halyna Pylypenko, MD, Holger W Auner, MD PhD, Xavier Leleu, MD, Vadim A Doronin, MD, Ganna Usenko, MD, Roman Hajek, MD, Reuben Benjamin, FRCPath, MRCP, MBBS, PhD, Tuphan Kanti Dolai, MBBS, MD DNB, DM, Dinesh Kumar Sinha, MD, Christopher P. Venner, MD, Mamta Garg, MD FRCP, FRCPath, Don A. Stevens, MD, Hang Quach, MDFRACP,FRCPA,MBBS, Sundar Jagannath, MD, Philippe Moreau, MD, Moshe Y. Levy, MD, Ashraf Z. Badros, MD, Larry D. Anderson, Jr., MD PhD, Nizar J. Bahlis, MD, Thierry Facon, MD, Maria-Victoria Mateos, MD PhD, Michele Cavo, Hua Chang, PhD, Yosef Landesman, PhD, Anita A. Joshi, Yi Chai, Melina Arazy, MD, Jatin Shah, MD, Sharon Shacham, PhD MBA, Michael G Kauffman, MD PhD, Sebastian Grosicki, MD PhD, Paul G. Richardson, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 35–36.
https://doi.org/10.1182/blood-2020-137154
Published: 2020
Journal Articles

Is Tandem ASCT Needed in MM Patients with High Risk Cytogenetics in the Era of Maintenance Therapy? Results from the Canadian Myeloma Research Group (CMRG) Database

Peter Duggan, MD FRCPC, Donna E. Reece, MD, Kevin Song, MD, Victor Jimenez-Zepeda, MD, Arleigh McCurdy, MD BSc, Martha L Louzada, MDMSc, Hira S Mian, MD, Michael Sebag, MD PhD FRCPC, Darrell J White, MD, Julie Stakiw, MD, Richard Leblanc, MD FRCPC, Esther Masih-Khan, Eshetu G Atenafu, M.Sc., P.Stat, Rami Kotb, MD, Muhammad Aslam, MD, Anthony Reiman, MD, Engin Gul, BS, MBA, Christopher P. Venner, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 18–19.
https://doi.org/10.1182/blood-2020-139689
Published: 2020
Journal Articles

Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study

Vaishali Sanchorawala, MD, Giovanni Palladini, MD PhD, Monique C. Minnema, Arnaud Jaccard, MD PhD, Hans C. Lee, MD, Simon D. Gibbs, FRACP, FRCPA, MBBS, Peter Mollee, FRACP,MBBS,MSc,FRCPA, Christopher P. Venner, MD, Jin Lu, Stefan Schönland, MD, Moshe Gatt, MD, Kenshi Suzuki, MD PhD, Kihyun Kim, MD, M. Teresa Cibeira, MD PhD, Meral Beksac, MD, Edward Libby, MD, Jason Valent, MD, Vania T. M. Hungria, MD PhD, Sandy W. Wong, MD, Michael Rosenzweig, MD, Naresh Bumma, MD, Dominique Chauveau, MD PhD, Katharine S. Gries, PhD PharmD, John Fastenau, RPh, MPH, PhD, NamPhuong Tran, MD, Xiang Qin, MD PhD, Sandra Y. Vasey, MSc, Brenda Tromp, MSc, Brendan M. Weiss, MD, Jessica Vermeulen, MD PhD, Giampaolo Merlini, MD, Raymond L. Comenzo, MD, Efstathios Kastritis, MD, Ashutosh D. Wechalekar, MBBS,FRCP,FRCPath,DM
Journal: Blood
Blood (2020) 136 (Supplement 1): 37–40.
https://doi.org/10.1182/blood-2020-139438
Published: 2020
Journal Articles

Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Arleigh McCurdy, MD BSc, Christopher P. Venner, MD, Martha L Louzada, MDMSc, Richard LeBlanc, MD FRCPC, Michael Sebag, MD PhD FRCPC, Kevin W Song, MD FRCPC, Victor Jimenez-Zepeda, MD, Rami Kotb, MD, Esther Masih-Khan, PhD, Eshetu G Atenafu, MSc, P.Stat, Hira S Mian, MD, Darrell J White, MD, Julie Stakiw, MD, Muhammad Aslam, MD, Anthony Reiman, MD, Engin Gul, BSc, Donna E. Reece, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 5–7.
https://doi.org/10.1182/blood-2020-142800
Published: 2020
Journal Articles

Overall and Progression Free Survival from the Mcrn-003/Myx.1 Trial: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma

Christopher P Venner, MD, Richard Leblanc, MDFRCPC, Irwindeep Sandhu, MDFRCPC, Darrell J White, MD, Andrew Belch, MD, Donna E Reece, MD, Christine I Chen, MD, Sean Dolan, MD, Marc Lalancette, MD FRCP, Martha L Louzada, MDMSc, Andrea Kew, MDFRCP(C), Arleigh McCurdy, MD, Tony Reiman, MD, Max Sherry, Gail T. McDonald, Bethany Elaine Monteith, MD, Engin Gul, BS, MBA, Bingshu E. Chen, Annette E. Hay
Journal: Blood
Blood (2019) 134 (Supplement_1): 1871.
https://doi.org/10.1182/blood-2019-122637
Published: 2019
Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia

Nizar Bahlis, MD, Thierry Facon, MD, Saad Z. Usmani, MD, Shaji K. Kumar, MD, Torben Plesner, MD DSc, Robert Z. Orlowski, MD, PhD, Cyrille Touzeau, MD, Supratik Basu, MBBS, MD FRCP, FRCPath, Hareth Nahi, MD PhD, Cyrille Hulin, MD, Hang Quach, MBBS, FRACP, FRCPA, MD, Hartmut Goldschmidt, Michael E O'Dwyer, MD, Christopher P Venner, MD, Katja C. Weisel, MD, Maria Krevvata, PhD, Huiling Pei, PhD, Jianping Wang, Rian Van Rampelbergh, Jon Ukropec, PhD, Clarissa M. Uhlar, Rachel Kobos, MD, Aurore Perrot
Journal: Blood
Blood (2019) 134 (Supplement_1): 1875.
https://doi.org/10.1182/blood-2019-123426
Published: 2019
Journal Articles

Treatment of Multiple Myeloma Patients Progressing on Lenalidomide-Based Regimens

Donna E Reece, MD, Esther Masih-Khan, PhD, Eshetu G Atenafu, MSc, P.Stat, Victor Jimenez-Zepeda, MD, Arleigh McCurdy, MD, Kevin Song, MD, Michael Sebag, MD PhD, Richard Leblanc, MDFRCPC, Martha L Louzada, MDMSc, Darrell J White, MD, Julie Stakiw, MD, Tony Reiman, MD, Rami Kotb, MD, Muhammad Aslam, MD, Engin Gul, BS, MBA, Christopher P Venner, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1886.
https://doi.org/10.1182/blood-2019-125479
Published: 2019
Journal Articles

Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Newly Diagnosed Multiple Myeloma

Darrell J White, MD, Suzanne Lentzsch, MD PhD, Cristina Gasparetto, MD, Nizar Bahlis, MD, Christine I Chen, MD, Brea C. Lipe, MD, Gary J. Schiller, MD, Sascha A Tuchman, MD, Heather J. Sutherland, MD PhD, Rami Kotb, MD, Richard Leblanc, MDFRCPC, Michael Sebag, MD PhD, Christopher P Venner, MD, Natalie Scott Callander, MD, William I. Bensinger, Heidi Sheehan, Yi Chai, Kazuharu Kai, MD, Jatin Shah, MD, Sharon Shacham, PhD MBA, Michael G. Kauffman, MD PhD, Muhamed Baljevic, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3165.
https://doi.org/10.1182/blood-2019-124370
Published: 2019
Journal Articles

Selinexor, Pomalidomide, and Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma

Christine I Chen, MD, Nizar Bahlis, MD, Cristina Gasparetto, MD, Sascha A Tuchman, MD, Brea C. Lipe, MD, Muhamed Baljevic, MD, Rami Kotb, MD, Heather J. Sutherland, MD PhD, William I. Bensinger, Michael Sebag, MD PhD, Richard Leblanc, MDFRCPC, Christopher P Venner, MD, Gary J. Schiller, MD, Suzanne Lentzsch, MD PhD, Natalie Scott Callander, MD, Heidi Sheehan, Yi Chai, Kazuharu Kai, MD, Jatin Shah, MD, Sharon Shacham, PhD MBA, Michael G. Kauffman, MD PhD, Darrell J White, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 141.
https://doi.org/10.1182/blood-2019-122907
Published: 2019